June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Impact of serous retinal detachment on the efficacy of ranibizumab therapy in diabetic macular edema
Author Affiliations & Notes
  • Franck Fajnkuchen
    France, Centre d'Imagerie et de Laser. Paris, Paris, France
    Hôpital Avicenne, Bobigny, France
  • Lise Qu
    Hôpital Avicenne, Bobigny, France
  • Valerie Sarda
    Hôpital Avicenne, Bobigny, France
  • Gilles Chaine
    Hôpital Avicenne, Bobigny, France
  • Audrey Giocanti-Auregan
    Hôpital Avicenne, Bobigny, France
  • Footnotes
    Commercial Relationships Franck Fajnkuchen, Allergan (C), Bayer (C), Novartis (C); Lise Qu, None; Valerie Sarda, None; Gilles Chaine, None; Audrey Giocanti-Auregan, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1756. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Franck Fajnkuchen, Lise Qu, Valerie Sarda, Gilles Chaine, Audrey Giocanti-Auregan; Impact of serous retinal detachment on the efficacy of ranibizumab therapy in diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1756.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To describe the evolution of diabetic macular edema (DME) treated with ranibizumab with regard to the presence of serous retinal detachment (SRD).

Methods: Diabetic patients treated with ranibizumab for DME were enrolled retrospectively. Patients were classified according to their optical coherence tomography (OCT) findings as follows: group 1 with SRD (G1) and group 2 without SRD (G2). Primary outcome was to assess the mean change in best-corrected visual acuity (BCVA) in letter score from baseline to month 6. Secondary outcomes were to determine the mean central retinal thickness (CRT) change, total number of intravitreal injections, proportion of good responders (BCVA gain ≥5 letters with CRT <300 μm with a restoration of foveal pit) and poor responders (loss of BCVA ≥5 letters and CRT >300 μm).

Results: 48 eyes with DME were included: 23 eyes in G1 and 25 eyes in G2. The proportion of SDR was 47.9%. Mean change BCVA was significantly greater in G1 than in G2: +21 ± 16.5 letters versus +7.8 ± 10.2 letters (p=0.002) from baseline to month 6. The mean CRT change was -339 ± 278 μm in G1 and -146 ± 136 μm in G2 (p=0.003). Mean injection number was 4.3 in G1 and 4.2 in G2 (p>0.05). Proportion of good responders was 65% in G1 versus 20% in G2 (p=0.002). Proportion of poor responders was similar (8.7% versus 12%, p=0.7).

Conclusions: In DME, the presence of SRD seems to be associated with a good response to ranibizumab.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.